There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veru (VERU – Research Report), Ascendis Pharma (ASND – Research Report) and Abbott Laboratories (ABT – Research Report) with bullish sentiments.
Pick the best stocks and maximize your portfolio:
Veru (VERU)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Veru, with a price target of $3.00. The company’s shares closed last Friday at $0.68.
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -17.5% and a 30.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as OKYO Pharma Limited Sponsored ADR, Bausch + Lomb Corporation, and Barinthus Biotherapeutics.
Currently, the analyst consensus on Veru is a Moderate Buy with an average price target of $5.00.
See Insiders’ Hot Stocks on TipRanks >>
Ascendis Pharma (ASND)
In a report released today, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Ascendis Pharma, with a price target of $220.00. The company’s shares closed last Friday at $138.97.
According to TipRanks.com, Clark-Gartner is a 4-star analyst with an average return of 18.1% and a 40.5% success rate. Clark-Gartner covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, Sarepta Therapeutics, and Jasper Therapeutics.
Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $192.54, a 40.5% upside from current levels. In a report issued on December 16, Wedbush also maintained a Buy rating on the stock with a $181.00 price target.
Abbott Laboratories (ABT)
TD Cowen analyst Josh Jennings reiterated a Buy rating on Abbott Laboratories today and set a price target of $135.00. The company’s shares closed last Friday at $114.63.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of 5.8% and a 50.8% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Zimmer Biomet Holdings, and Allurion Technologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Laboratories with a $133.33 average price target, representing a 18.4% upside. In a report issued on December 11, Oppenheimer also maintained a Buy rating on the stock with a $130.00 price target.
Read More on VERU: